Feasibility Study of an Outdoor Strength Training Program for Older Adults
NCT07928687, Not applicable, Recruiting, Universitaire Ziekenhuizen KU Leuven
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Feasibility Study of an Outdoor Strength Training Program for Older Adults | ClinicalTrials.gov |
| NCT number | NCT07928687 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 24 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Universitaire Ziekenhuizen KU Leuven | ClinicalTrials.gov |
| Conditions | Exercise Training | ClinicalTrials.gov |
| Interventions | 6-week outdoor strength training program using activity benches and a smartphone application | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Number of Participants Experiencing Adverse Events | Throughout the 6-week intervention | Safety of the intervention, assessed as the number of participants experiencing one or more adverse events related to testing or training sessions during the intervention period. | ClinicalTrials.gov |
| Primary | Participant Adherence Rate | Throughout the 10-week study period | Adherence to the intervention, assessed as the proportion of participants who complete the intervention and post-intervention assessments. And assessed as the percentage of scheduled training sessions attended by participants during the 6-week intervention. | ClinicalTrials.gov |
| Primary | System Usability Scale (SUS) | Post-intervention at week 9 | Usability of the intervention will be assessed using the System Usability Scale (SUS), a 10-item questionnaire yielding a total score ranging from 0 to 5. Five items are positively worded, for which higher response scores indicate greater usability, while five items are negatively worded and are reverse-scored, such that lower response scores indicate greater usability. | ClinicalTrials.gov |
| Primary | Net Promoter Score (NPS) | Post-intervention at week 9 | Acceptability of the intervention, assessed using the Net Promoter Score (NPS), based on participants' likelihood of recommending the programme to others. Scores range from 0 to 10, with higher scores indicating greater acceptability and willingness to recommend the intervention. | ClinicalTrials.gov |
| Primary | Participant Acceptability of the Intervention | Post-intervention at week 9 | Acceptability of the intervention, assessed through participant feedback regarding the peer-led delivery model and the appropriateness of training intensity and progression. Responses will be summarized descriptively. | ClinicalTrials.gov |
| Primary | Completion Rate of Data Collection Procedures | Over the 10-week study period | Feasibility of data collection procedures, assessed as the proportion of planned laboratory-based assessments, questionnaire assessments, and IPitup app-based assessments successfully completed by participants. Higher percentages indicate greater feasibility of the data collection procedures. | ClinicalTrials.gov |
| Primary | Change in Lower Limb Muscle Strength and Power | Baseline at week 1 and post-intervention at week 9 | Preliminary effects of the intervention on muscle strength and power, assessed as the change in lower limb muscle strength and power from baseline to post-intervention. Muscle strength and power will be measured using the predefined study strength assessment protocol. Higher values indicate greater muscle strength and power. | ClinicalTrials.gov |
| Primary | Implementation Barriers and Facilitators Identified During Focus Groups | Post-intervention at week 10 | Implementation barriers and facilitators will be explored through semi-structured focus groups conducted following the intervention. Audio recordings will be transcribed verbatim and analysed using qualitative thematic analysis. Identified barriers and facilitators will be categorized into themes to inform optimization of a future randomized controlled trial. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)